Correction: Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes

  • Sharon J. Peacock,
  • Direk Limmathurotsakul,
  • Yoel Lubell,
  • Gavin C. K. W. Koh,
  • Lisa J. White,
  • Nicholas P. J. Day,
  • Richard W. Titball
  • Published: February 26, 2013
  • DOI: 10.1371/annotation/20664ec9-17e4-4ba6-8c65-481a70a5c4ad

Table S1 contains two items that require correction. The OMV vaccine given subcutaneously is listed as providing 0% protection against challenge; in fact, it provided 60% protection. Additionally, the challenge information should indicate 1000 CFU by aerosol instead of 5000 CFU intranasally. Please view the correct Table S1 here:

Download corrected item.